ARTICLE DOWNLOAD

RYGB in Treating Patients with Obesity, Hypertriglyceridemia-Induced Acute Pancreatitis, and Diabetes: Kill Three Birds with One Stone?

10$
ARTICLE DOWNLOAD

RYGB in Treating Patients with Obesity, Hypertriglyceridemia-Induced Acute Pancreatitis, and Diabetes: Kill Three Birds with One Stone?

10$

Yixing Ren, Ming He, Yin Xian, Huirun Zeng & Yongyan Song 

Introduction

Obesity is closely linked to a cluster of metabolic disorders, such as hyperlipidemia, hypertriglyceridemia-induced acute pancreatitis (HTG-AP), and diabetes [1]. Bariatric surgery has been widely used to treat morbid obesity and its metabolic complications. In our previous study [2], we performed laparoscopic sleeve gastrectomy (LSG) for 9 patients with obesity and HTG-AP and found that LSG was very effective for this kind of patients, as indicated by a large weight loss, a significant reduction in triglycerides (TG), and no recurrence of HTG-AP during 12 months after the surgery.

In clinical practice, we also encountered some patients who not only had obesity and recurrent HTG-AP but also had severely elevated blood glucose levels. These patients reported they did not have diabetes before the onset of HTG-AP, so we speculated that diabetes was caused by obesity or HTG-AP, or both in this group of patients. Several studies [3, 4] demonstrated that Roux-en-Y gastric bypass (RYGB) was an effective treatment not only for obesity and hyperlipidemia but also for middle- and long-term control of diabetes, which is even superior to LSG. Taken together, RYGB may be a good way to treat the patients combined with obesity, HTG-AP, and diabetes. In this study, RYGB was performed for 6 patients combined with obesity, HTG-AP, and diabetes to preliminarily investigate if this bariatric procedure can effectively solve all of these problems in this kind of patients.

Only units of this product remain
Year 2020
Language English
Format PDF
DOI 10.1007/s11695-020-04466-8